EP0632129A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors
Assignee: Bayer AG
•
Filing: 1994-05-24
•
Granted: —
•
Expires: 2014-05-24
Abstract
Abstract The present invention relates to the preparation of novel vector systems which are generated by in-vitro recombination, using gene technology, of nucleic acids from foamy virus species and of exogenous nucleic acid, and are produced by suitable host cells or by recombinantly altered packaging cell lines. The recombinant preparation of particularly suitable packaging cell lines is likewise a constituent of this invention. The invention is distinguished by the safe and efficient transfer by foamy virus vectors of therapeutic and other genes into eukaryotic cells.
Inventors
- 👤 Volker Prof.Dr. Ter Meulen
- 👤 Axel Dr. Rethwilm
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-03 19:10
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61P; A61P25/00; A61P25/28; A61P31/00; A61P31/12; A61P35/00; A61P37/00; A61P37/02; A61P37/06; A61P9/00; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N15/86; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/17011; C12N2740/17022; C12N2740/17041; C12N2740/17043; C12N2840/00; C12N2840/20; C12N2840/203; C12N2840/44; C12N2840/80; C12N2840/85
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
23 words
Foamy virus vector, which contains an exogenous nucleic acid for expressing one or more gene products having a therapeutic, immunising or diagnostic effect.
Claim 2
Dependent Claim
50 words
Foamy virus vector according to Claim 1, characterized in that the foamy virus vector is a derivative of human foamy virus (infectious or non-infectious DNA of human spumaretrovirus HSRV-1 oor HSRV-2) possessing a deletion in the region of the bel-1, bel-2 and/or bel-3 genes for inserting the exogenous nucleic acid.
Claim 3
Dependent Claim
32 words
Foamy virus vector according to Claims 1 to 2, characterized in that the exogenous nucleic acid contains a complete gene, or several complete genes, for expressing polypeptides for humoral and/or cellular immunization.
Claim 4
Dependent Claim
29 words
A foamy virus vector according to Claims 1 to 2, characterized in that the exogenous nucleic acid contains a gene for expressing antisense RNA, ribozyme RNA or decoy RNA.
Claim 5
Dependent Claim
24 words
A foamy virus vector according to Claims 1 to 2, characterized in that the exogenous nucleic acid expresses gene products for inhibiting tumour formation.
Claim 6
Dependent Claim
27 words
Foamy virus vector according to Claims 1 to 2, characterized in that the exogenous nucleic acid expresses gene products which remedy gene defects in the target organism.
Claim 7
Dependent Claim
21 words
Foamy virus vectors according to Claims 1 to 6 for treating autoimmune diseases, cardiovascular diseases, tumours, viral diseases or gene defects.
Claim 8
Dependent Claim
23 words
Foamy virus vectors according to Claims 1 to 6, which contain an exogenous nucleic acid sequence for expressing a product for diagnostic use.
Claim 9
Dependent Claim
11 words
Medicaments containing foamy virus vectors according to Claims 1 to 7.
Claim 10
Dependent Claim
19 words
Eukaryotic cell lines, or recombinant eukaryotic cell lines, for producing foamy virus vectors according to Claims 1 to 9.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.